Viral sequence diversity: challenges for AIDS vaccine designs

References

• Joint United Nations Programme on HIV/AIDS, World Health Organization. AIDS epidemic update report (2007).
   Google Scholar
• Letvin NL. Progress and obstacles in the development of an AIDS vaccine. Nature Rev. Immunol.6(12), 930–939 (2006).
   PubMedGoogle Scholar
• Sekaly R-P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med.205(1), 7–12 (2008).
   PubMed Web of Science ®Google Scholar
• McMichael AJ. HIV VACCINES. Annu. Rev. Immunol.24(1), 227–255 (2006).
   PubMed Web of Science ®Google Scholar
• Thorner AR, Barouch DH. HIV-1 vaccine development: progress and prospects. Curr. Infect. Dis. Rep. (9), 71–75 (2007).
   PubMedGoogle Scholar
• Freed EO, Martin MA. Fields Virology. Howley PM, Knipe DM (Eds). Lippincott Williams and Wilkins, PA, USA (2001).
   Google Scholar
• Hallenberger S, Bosch V, Angliker H et al. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gpl60. Nature360(6402), 358–361 (1992).
   PubMed Web of Science ®Google Scholar
• Prabakaran P, Dimitrov AS, Fouts TR, Dimitrov DS, KuanTeh J. Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors. In: Advances in Pharmacology. Academic Press, MA, USA (2007).
   Google Scholar
• Gaschen B, Taylor J, Yusim K et al. Diversity considerations in HIV-1 vaccine selection. Science296(5577), 2354–2360 (2002).
   PubMed Web of Science ®Google Scholar
• Robertson DL, Anderson JP, Bradac JA et al. A reference guide to HIV-1 classification. In: Human Retroviruses and AIDS. Korber B, Kuiken C, Foley B et al. (Eds). 492–505 (1999).
   Google Scholar
• Johnston MI. Progress in HIV vaccine development. Curr. Opin. Pharmacol.1, 504–510 (2001).
   PubMedGoogle Scholar
• Berman P, Gregory T, Riddle L et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature345, 622–625 (1990).
   PubMed Web of Science ®Google Scholar
• Polacino P. Limited breadth of protetive immunity elicited by SIVmne gp160 vaccines in combination immunization regimen. J. Virol.73, 618–630 (1999).
   PubMedGoogle Scholar
• Barry AP, Silvestri G, Safrit JT et al. Depletion of CD8+ cells in sooty mangabey monkeys naturally infected with simian immunodeficiency virus reveals limited role for immune control of virus replication in a natural host species. J. Immunol.178(12), 8002–8012 (2007).
   PubMedGoogle Scholar
• Murthy KK, Cobb EK, Rouse SR et al. Active and passive immunization against HIV type 1 infection in chimpanzees. AIDS Res. Hum. Retroviruses14(Suppl. 3), S271–S276 (1998).
   Google Scholar
• Conley AJ, Kessler JA, II, Boots LJ et al. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol.70(10), 6751–6758 (1996).
   PubMedGoogle Scholar
• Clements JE, Montelaro RC, Zink MC et al. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J. Virol.69(5), 2737–2744 (1995).
   PubMedGoogle Scholar
• Gardner M, Rosenthal A, Jennings M et al. Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res. Hum. Retroviruses11(7), 843–854 (1995).
   PubMed Web of Science ®Google Scholar
• Haigwood NL, Watson A, Sutton WF et al. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol. Lett.51(1–2), 107–114 (1996).
   PubMed Web of Science ®Google Scholar
• Van Rompay KK, Berardi CJ, Dillard-Telm S et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J. Infect. Dis.177(5), 1247–1259 (1998).
   PubMed Web of Science ®Google Scholar
• Mascola JR, Lewis MG, Stiegler G et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol.73(5), 4009–4018 (1999).
   PubMed Web of Science ®Google Scholar
• Mascola JR, Stiegler G, VanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med.6(2), 207–210 (2000).
   PubMed Web of Science ®Google Scholar
• Baba TW, Liska V, Hofmann-Lehmann R et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection. Nat. Med.6(2), 200–206 (2000).
   PubMed Web of Science ®Google Scholar
• Foresman L, Jia F, Li Z et al. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques. AIDS Res. Hum. Retroviruses14(12), 1035–1043 (1998).
   PubMedGoogle Scholar
• Li A, Baba TW, Sodroski J et al. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res. Hum. Retroviruses13(8), 647–656 (1997).
   PubMed Web of Science ®Google Scholar
• Li A, Katinger H, Posner MR et al. Synergistic neutralization of simian–human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. J. Virol.72(4), 3235–3240 (1998).
   PubMed Web of Science ®Google Scholar
• Shibata R, Igarashi T, Haigwood N et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med.5(2), 204–210 (1999).
   PubMed Web of Science ®Google Scholar
• Barnett SW. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine15, 869–873 (1997).
   PubMed Web of Science ®Google Scholar
• Burton DR, Montefiori DC. The antibody response in HIV-1 infection. AIDS11, S87–S98 (1997).
   Google Scholar
• Graham BS. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers preimed with gp160-recombinant vaccinina virus. J. Infect. Dis.170, 782–786 (1994).
   PubMedGoogle Scholar
• Mascola JR, Snyder SW, Weislow OS et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against labratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis.173, 340–348 (1996).
   PubMed Web of Science ®Google Scholar
• Mascola JR. Protection of macaques against vaginal transmission of pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med.6, 207–210 (2000).
   PubMed Web of Science ®Google Scholar
• Parren PW. Neutralization of HIV-1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of eptiope specificity. J. Virol.73, 3512–3519 (1998).
   Google Scholar
• Van Cott TC. Antibodies with specificity to native gp120 and neutralizaion activity against primary HIV-1 isolates elciited by immunization with oligomeric gp160. J. Virol.71, 4319–4330 (1997).
   PubMedGoogle Scholar
• Yang X. Characterization of stable, soluble trimer contaiing complete ectodomains of HIV-1 envelope glycoprotein. J. Virol.74, 5716–5725 (2000).
   PubMedGoogle Scholar
• Cho MW. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J Virol.75, 2224–2234 (2001).
   PubMed Web of Science ®Google Scholar
• Cole KS, Rowles JL, Murphey-Corb M et al. A model for the maturation of protective antibody responses to SIV envelope proteins in experimentally immunized monkeys. J. Med. Primatol.26(1–2), 51–58 (1997).
   PubMedGoogle Scholar
• Cole KS, Murphey-Corb M, Narayan O et al. Common themes of antibody maturation to simian immunodeficiency virus, simian–human immunodeficiency virus, and human immunodeficiency virus type 1 infections. J. Virol.72(10), 7852–7859 (1998).
   PubMedGoogle Scholar
• Fuller DH, Simpson L, Cole KS et al. Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunol. Cell Biol.75(4), 389–396 (1997).
   PubMed Web of Science ®Google Scholar
• Johnson RP, Lifson JD, Czajak SC et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Virol.73(6), 4952–4961 (1999).
   PubMed Web of Science ®Google Scholar
• Hammond SA, Cook SJ, Lichtenstein DL, Issel CJ, Montelaro RC. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol.71(5), 3840–3852 (1997).
   PubMedGoogle Scholar
• Montelaro RC, Cole KS, Hammond SA. Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development. AIDS Res. Hum. Retroviruses14(Suppl. 3), S255–S259 (1998).
   PubMedGoogle Scholar
• Van Rompay K, Greenier JL, Cole KS et al. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J. Virol.77, 179–190 (2003).
   PubMed Web of Science ®Google Scholar
• Emini EA, Schleif WA, Nunberg JH et al. Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody. Nature355(6362), 728 (1992).
   PubMed Web of Science ®Google Scholar
• Holl V, Peressin M, Decoville T et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J. Virol.80(12), 6177–6181 (2006).
   PubMed Web of Science ®Google Scholar
• Mascola JR, Lewis MG, Stiegler G et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6pd by passive transfer of neutralizing antibodies. J. Virol.73(5), 4009–4018 (1999).
   PubMed Web of Science ®Google Scholar
• Manrique M, Micewicz E, Kozlowski PA et al. DNA-MVA Vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. AIDS Res. Hum. Retroviruses24(3), 505–519 (2008).
   PubMedGoogle Scholar
• Nilsson C, Makitalo B, Thorstensson R et al. Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS12(17), 2261–2270 (1998).
   PubMed Web of Science ®Google Scholar
• Wyand MS, Manson K, Montefiori DC et al. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol.73(10), 8356–8363 (1999).
   PubMed Web of Science ®Google Scholar
• Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol.70(6), 3724–3733 (1996).
   PubMed Web of Science ®Google Scholar
• Xu R, Srivastava IK, Kuller L et al. Immunization with HIV-1 SF162-derived envelope gp140 proteins does not protect macaques from heterologous simian–human immunodeficiency virus SHIV89.6P infection. Virology349(2), 276–289 (2006).
   PubMedGoogle Scholar
• Someya K, Cecilia D, Ami Y et al. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette–Guerin env V3 elicits neutralizing antibody-mediated protection against simian–human immunodeficiency virus with a homologous but not a heterologous V3 motif. J. Virol.79(3), 1452–1462 (2005).
   PubMed Web of Science ®Google Scholar
• Nickle DC, Jensen MA, Gottlieb GS et al. Consensus and ancestral state HIV vaccines. Science299(5612), 1515–1518 (2003).
   PubMed Web of Science ®Google Scholar
• Weaver EA, Lu Z, Camacho ZT et al. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group M consensus env immunogen. J. Virol.80(14), 6745–6756 (2006).
   PubMed Web of Science ®Google Scholar
• Gao F, Weaver EA, Lu Z et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein. J. Virol.79(2), 1154–1163 (2005).
   PubMed Web of Science ®Google Scholar
• Kuiken CL, Foley B, Freed E et al. (Eds). HIV Sequence Compendium. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, NM, LA-UR 03-3564, USA (2002).
   Google Scholar
• Zhan X. Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells. Vaccine22, 1206–1213 (2004).
   PubMedGoogle Scholar
• Yusim K, Kesmir C, Gaschen B. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J. Virol.76, 8757–8768 (2002).
   PubMedGoogle Scholar
• Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol.4, 199–210 (2004).
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Learn GH, Rodrigo AG et al. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J. Virol.79(17), 11214–11224 (2005).
   PubMed Web of Science ®Google Scholar
• Kothe DL, Decker JM, Li Y et al. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology360(1), 218–234 (2007).
   PubMed Web of Science ®Google Scholar
• Kothe DL, Li Y, Decker JM et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology352(2), 438–449 (2006).
   PubMed Web of Science ®Google Scholar
• Scriba TJ, zur Megede J, Glashoff RH et al. Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences. Vaccine23(9), 1158 (2005).
   PubMedGoogle Scholar
• Liao H-X, Sutherland LL, Xia S-M et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology353(2), 268–282 (2006).
   PubMed Web of Science ®Google Scholar
• Davies MN, Flower DR. Harnessing bioinformatics to discover new vaccines. Drug. Discov. Today12(9–10), 389–395 (2007).
   PubMed Web of Science ®Google Scholar
• Burgers WA, van Harmelen JH, Shephard E et al. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J. Gen. Virol.87(2), 399–410 (2006).
   PubMed Web of Science ®Google Scholar
• De Groot AS, Bishop EA, Khan B et al. Engineering immunogenic consensus T-helper epitopes for a cross-clade HIV vaccine. Methods34(4), 476 (2004).
   PubMedGoogle Scholar
• Hamano T, Sawanpanyalert P, Yanai H et al. Determination of HIV type 1 CRF01_AE gag p17 and env-V3 consensus sequences for HIV/AIDS vaccine design. AIDS Res. Hum. Retroviruses20(3), 337–340 (2004).
   PubMedGoogle Scholar
• Hanke T, McMichael AJ, Mwau M et al. Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine20(15), 1995 (2002).
   PubMed Web of Science ®Google Scholar
• Krohn K, Stanescu I, Blazevic V et al. A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A–C subtypes and the ancestor sequence of the F–H subtypes. Preclinical and clinical studies. Microbes Infect.7(14), 1405 (2005).
   PubMed Web of Science ®Google Scholar
• Kumar S, Aggarwal P, Vajpayee M, Pandey RM, Seth P. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India. Vaccine24(14), 2585 (2006).
   PubMedGoogle Scholar
• Malm M, Rollman E, Ustav M et al. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral Immunol.18(4), 678–688 (2005).
   PubMed Web of Science ®Google Scholar
• Nkolola J, Wee EG-T, Im E-J. Engineering RENTA, a DNA prime–MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther.11(13), 1069–1080 (2004).
   Google Scholar
• Thomson SA, Jaramillo AB, Shoobridge M et al. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine23(38), 4647 (2005).
   PubMedGoogle Scholar
• Slobod K, Coleclough C, Bonsignori M et al. HIV vaccine rationale, design and testing. Curr. HIV Res.3(2), 107–112 (2005).
   PubMedGoogle Scholar
• Azizi A, Anderson D, Ghorbani M, Gee K, Diaz-Mitoma F. Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters. BMC Immunol.7(1), 25 (2006).
   PubMedGoogle Scholar
• Chakrabarti BK, Ling X, Yang Z-Y et al. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine23(26), 3434 (2005).
   PubMedGoogle Scholar
• Ljungberg K, Rollman E, Eriksson L, Hinkula J, Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology302(1), 44 (2002).
   PubMedGoogle Scholar
• Rollman E, Hinkula J, Arteaga J et al. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther.11(14), 1146–1154 (2004).
   PubMed Web of Science ®Google Scholar
• Wang S, Pal R, Mascola JR et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology350(1), 34–47 (2006).
   PubMed Web of Science ®Google Scholar
• Brave A, Boberg A, Gudmundsdotter L et al. A new multi-clade DNA prime/recombinant MVA Boost vaccine induces broad and high levels of HIV-1-specific CD8+ T-cell and humoral responses in mice. Mol. Ther.15(9), 1724–1733 (2007).
   PubMedGoogle Scholar
• Brave A, Ljungberg K, Boberg A et al. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol. Ther.12(6), 1197 (2005).
   PubMedGoogle Scholar
• Cristillo AD, Wang S, Caskey MS et al. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology346(1), 151 (2006).
   PubMed Web of Science ®Google Scholar
• Kong W-P, Huang Y, Yang Z-Y et al. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J. Virol.77(23), 12764–12772 (2003).
   PubMedGoogle Scholar
• Pal R, Wang S, Kalyanaraman VS et al. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J. Med. Primatol.34(5–6), 226–236 (2005).
   PubMed Web of Science ®Google Scholar
• Pal R, Wang S, Kalyanaraman VS et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology348(2), 341–353 (2006).
   PubMed Web of Science ®Google Scholar
• Pal R, Yu Q, Wang S et al. Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits. Vaccine24(8), 1225 (2006).
   PubMedGoogle Scholar
• Seaman MS, Xu L, Beaudry K et al. multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol.79(5), 2956–2963 (2005).
   PubMed Web of Science ®Google Scholar
• Wang S, Kennedy JS, West K et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime–protein boost HIV-1 vaccine in healthy human volunteers. Vaccine26(8), 1098–1110 (2008).
   PubMedGoogle Scholar
• Fischer W, Perkins S, Theiler J et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med.13(1), 100–106 (2007).
   PubMed Web of Science ®Google Scholar
• Azizi A, Anderson DE, Torres JV et al. Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques. J. Immunol.180(4), 2174–2186 (2008).
   PubMedGoogle Scholar
• Hanke T. STEP trial and HIV-1 vaccines inducing T-cell responses. Expert Rev. Vaccines7(3), 303–309 (2008).
   PubMed Web of Science ®Google Scholar
• Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med.14(6), 617–621 (2008).
   PubMed Web of Science ®Google Scholar
• Cole K, Rowles J, Jagerski B et al. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J. Virol.71, 5069–5079 (1997).
   PubMedGoogle Scholar
• Dorner F, Barrett PN. Vaccine technology: looking to the future. Ann. Med.31(1), 51–60 (1999).
   PubMed Web of Science ®Google Scholar
• Graham B. Clinical trials of HIV vaccines. Annu. Rev. Med.53, 207–221 (2002).
   PubMedGoogle Scholar
• Mascola JR. Defining the protective antibody response for HIV-1. Curr. Mol. Med.3, 209–216 (2003).
   PubMed Web of Science ®Google Scholar
• Crooks ET, Moore PL, Franti M et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology366(2), 245–262 (2007).
   PubMed Web of Science ®Google Scholar
• McBurney SP, Young KR, Ross TM. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology358(2), 334–346 (2007).
   PubMed Web of Science ®Google Scholar
• Gaschen B. Diversity considerations in HIV-1 vaccine selection. Science296, 2354–2360 (2002).
   PubMed Web of Science ®Google Scholar
• Gao F. Consensus and ancestral state of HIV vaccines. Science299, 1515–1518 (2003).
   Google Scholar